Canada markets closed

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1400+0.2100 (+5.34%)
At close: 04:00PM EDT
4.1000 -0.04 (-0.97%)
After hours: 04:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.9300
Bid4.1000 x 1100
Ask4.1800 x 800
Day's Range3.9019 - 4.1828
52 Week Range2.5600 - 7.3800
Avg. Volume318,165
Market Cap55.525M
Beta (5Y Monthly)-0.44
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

    Aware® is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast.EZ Detect™ is a simple 2-minute, at-home test which detects an early warning sign of colorectal cancer IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amaz

  • GlobeNewswire

    Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

    InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development Executive IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced plans to launch its InFoods® IBS test before calendar year end. The test will be performed in a CLIA-certified, high-complexity laboratory facility and offered as a laboratory develo

  • GlobeNewswire

    Biomerica Reports Fiscal 2022 Year End Results

    Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results. Net sales for the fiscal year ended May 31, 2022 were $18.9 million as compared to net sales of $7.2 million in fiscal 2021, an increase of $11.7 million, or 162%. Net loss was $4.6 million for f